NVAX Soars on Coronavirus Vaccine Deal with U.S. Government

The equity is up an unheard of 2,664.3% year-to-date

Digital Content Manager
Jul 7, 2020 at 11:38 AM
facebook twitter linkedin


The shares of Novavax, Inc. (NASDAQ: NVAX) are up 24.2% at $98.72 this morning, after the U.S. government awarded the drug development company $1.6 billion to cover testing, commercialization, and manufacturing of a potential coronavirus vaccine. The investment is part of a White House program that seeks to accelerate access to COVID-19 treatments, and deliver 100 million vaccines by January 2021. 

The race for a coronavirus treatment has lifted NVAX up on the charts. Though shares have been on the rise since May, today's news boosted the equity to a nearly four-year high of $111.77. The stock's 10-day moving average has served as support over the past few weeks, containing most of NVAX's pullbacks late last week. Longer term, the equity is performing incredibly well, and sports a jaw-dropping 2,378.2% lead this year. 

Analysts were mostly optimistic toward NVAX, with five of the seven in coverage sporting a "strong buy," and only two carrying a tepid "hold." Meanwhile, the consensus 12-month price target of $86.25 is a significant 12.34% discount to current levels, meaning price-target hikes could be on the horizon. Short sellers are coming in droves, however. Short interest is up 10.2% in the last two reporting periods, and the 8.11 million shares sold short make up a hefty 34.5% of NVAX's available float.

That sentiment is echoed in the options pits, where the stock's Schaeffer's put/call open interest ratio (SOIR) comes in at 1.17. This ranks in the 94th percentile of readings from the past year -- highlighting a strong appetite for puts over calls among short-term speculators.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners